Conduit Pharmaceuticals Inc (NASDAQ:CDT) price on Friday, October 25, fall -8.34% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $0.11.
A look at the stock’s price movement, the close in the last trading session was $0.12, moving within a range at $0.109 and $0.122. The beta value (5-Year monthly) was 2.086. Turning to its 52-week performance, $7.83 and $0.09 were the 52-week high and 52-week low respectively. Overall, CDT moved -12.97% over the past month.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Conduit Pharmaceuticals Inc’s market cap currently stands at around $10.76 million, with investors looking forward to this quarter’s earnings report slated for in November.
Turning to the stock’s technical picture we see that short term indicators suggest on average that CDT is a 50% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
CDT’s current price about 2.93% and -11.57% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 45.59, while 7-day volatility ratio is 14.45% and 14.10% in the 30-day chart. Further, Conduit Pharmaceuticals Inc (CDT) has a beta value of 2.08, and an average true range (ATR) of 0.02.
If we refocus on Conduit Pharmaceuticals Inc (NASDAQ:CDT), historical trading data shows that trading volumes averaged 49.19 over the past 10 days and 19.20 million over the past 3 months. The company’s latest data on shares outstanding shows there are 73.83 million shares.
The 46.26% of Conduit Pharmaceuticals Inc’s shares are in the hands of company insiders while institutional holders own 3.09% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 1.45 million on 2024-09-30, giving us a short ratio of 0.11. Current price change has pushed the stock -97.54% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the CDT stock continues to rise going into the next quarter.
